Dermatology Times: July 20, 2025

123456789101112131415161718192021
Across
  1. 5. Haut.AI launched this educational initiative as part of UV Safety Awareness Month.
  2. 7. Trifarotene is a new generation of this class of topical medication.
  3. 11. A new partnership seeks to advance this IL-36 inhibitor for GPP.
  4. 13. New AD treatment guidance is needed for patients during this life stage.
  5. 14. A recommended ingredient in photoprotection products safe for pregnancy.
  6. 15. Topical retinoids remain central to treatment of this common inflammatory condition.
  7. 16. Patient stories emphasized early detection and public education for this skin cancer.
  8. 17. A French survey found gaps in severity assessments for this chronic hand condition.
  9. 18. This creative medium is helping foster patient connection and reduce bias in dermatology.
  10. 19. Newly launched in the US, this treatment targets severe alopecia areata.
  11. 20. GX-03 is a first-in-class topical IL-36 inhibitor targeting moderate to severe forms of this condition.
Down
  1. 1. Treg cell dysfunction plays a key role in this depigmenting skin condition.
  2. 2. This chronic inflammatory condition was the focus of procedural coverage in the July cover story.
  3. 3. Periocular procedures involving this technology require strict safety protocols.
  4. 4. A global survey revealed a misalignment in AD treatment _______ for pregnant patients.
  5. 6. (Shortened name) Deficiency of this immune cell type is implicated in vitiligo pathogenesis.
  6. 8. A topical retinoid that shows strong results in adult acne and acne sequelae.
  7. 9. This JAK1 inhibitor reduced itch and lesion severity in a recent atopic dermatitis trial.
  8. 10. This biologic was referenced in a case for switching to upadacitinib in AD.
  9. 12. AI tools analyzed over 1 million users to uncover trends in this type of hair loss.
  10. 21. Genetic insights are improving understanding and treatment of abbreviation for chronic urticaria.